Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of ...

Biotech stocks rebound after years of weakness as M&A, lower rates and easing policy fears draw investors back to the sector.

Enfortumab vedotin plus pembrolizumab improved EFS, OS, and pCR rates in MIBC patients ineligible for cisplatin-based chemotherapy. The combination therapy showed a median EFS and OS that were not ...

Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...

Stocks rose to begin a busy week that will see a flurry of corporate earnings reports, with investors also awaiting further ...

The Trop-2 protein is highly expressed in EGFR -mutated NSCLC, and resistance to EGFR TKIs such as osimertinib is associated ...

The impact of digital transformation, increased regulation, rising costs, bouncing tariffs and volatile geopolitics are just some of the big issues keeping Australian business leaders up at night.

Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including ...

Yahoo Finance is chronicling the latest news and updates on President Trump's plans to impose tariffs on goods from other ...

Yahoo Finance is chronicling the latest news and updates on President Trump's plans to impose tariffs on goods from other ...